The extended review for Elinzanetant is supported by data from the Phase III OASIS 1, 2, and 3 trials, which supported the ...

Barclays (LON: BARC) views the development as “a small negative for Bayer,” though analysts remain positive on the drug’s ...

The Food and Drug Administration (FDA) has extended the review period for elinzanetant, an investigational hormone-free therapy for the treatment of moderate to severe vasomotor symptoms (VMS) due to ...

Berlin: Bayer has announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug ...

After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet ...

US FDA extends review period for Bayer’s NDA for elinzanetant to treat moderate to severe VMS due to menopause: Berlin Monday, July 28, 2025, 16:00 Hrs [IST] Bayer announced tha ...

Note that some links may require registration or subscription. HHS Secretary Robert F. Kennedy Jr. is facing new questions ...

The government has revealed details of its plans to cut foreign aid, with support for women's health and children's education in Africa facing the biggest reductions. Nuala McGovern gets reaction from ...

Another study linked GLP-1 receptor agonist use with higher odds of developing nonarteritic anterior ischemic optic neuropathy, a potentially blinding eye condition. Last month, the European Medicines ...

FDA delays Bayer’s elinzanetant review to Oct 2025 amid liver safety concerns; global approvals still on track.

Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) shares traded higher in Germany on Friday after the company lifted its full-year guidance ...